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Polybrominated diphenyl ethers (PBDEs)
are widely used as additive flame retardants
in many different polymers, resins, and sub-
strates at concentrations ranging from 5% to
30% (1). Because of the widespread
production and use of PBDEs, their high
binding affinity to particles, and their
lipophilic characteristics, several PBDE
congeners bioconcentrate and bioaccumu-
late in the environment in a manner similar
to the structurally related polychlorinated
biphenyls (PCBs) (1–3). PBDEs have been
detected in various biotic samples such as
birds, seals, whales, and even in human
blood, adipose tissue, and breast milk
(4–10). The congeners 2,2´,4,4´-tetraBDE
(BDE-47), 2,2´,4,4´,5-pentaBDE (BDE-
99), and 2,2´,4,4´,6-pentaBDE (BDE-100)
are generally the dominant congeners found
in wildlife and humans. The relevance of
PBDEs as environmental contaminants has
been demonstrated by their accumulation in
human breast milk, where concentrations in
Swedish women have increased over the last
2 decades from 0.07 ng/g lipid weight in
1972 to 4.02 ng/g lipid weight in 1998 (8).
Although PCB concentrations in wildlife are
still higher than PBDE concentrations, they
are declining over the same time period. 
The most sensitive end points of PBDE
toxicity in vivo are effects on thyroid func-
tion, observed as induction of thyroid hyper-
plasia and alteration of thyroid hormone
production [i.e., lowering of free and total
thyroxine (T4) concentrations] in rats and
mice (11,12). Consistent with these findings
is the recent observation that several pure
PBDE congeners were able to displace T4
from transthyretin (TTR; a plasma transport
protein of thyroid hormones) in vitro, after
metabolic conversion to hitherto unidentified
metabolites (13). These phenomena have also
been observed for other organohalogen com-
pounds such as PCBs and their hydroxylated
metabolites (14,15, and references therein).
Another property that PBDEs share with
PCBs and the polybrominated biphenyls
(PBBs) is the dioxinlike, Ah receptor-medi-
ated induction of cytochrome P450 1A1 and
1A2 in vitro (16) and in vivo (17). Recently
we demonstrated by means of an Ah recep-
tor-mediated, chemically activated luciferase
expression cell line (the Ah-CALUX-assay)
(18–20) that several pure di- to hepta-bromi-
nated PBDE congeners were able to act via
this Ah receptor pathway in vitro as agonists
and antagonists in a congener-specific man-
ner (21). For example 2,3,4,4´,5,6-hexaBDE
(BDE-166) and 2,3,3´,4,4´,5,6-heptaBDE
(BDE-190) were relatively strong Ah recep-
tor agonists with potencies comparable to
the mono-ortho 2,3,3´,4,4´-pentaCB (CB-
105) and 2,3´,4,4´,5-pentaCB (CB-118)
(22).
Some studies have indicated that hydrox-
ylated PBDEs (HO-PBDEs) are of potential
environmental importance. In liver micro-
somes of rats, several PBDE congeners were
biotransformed to metabolites (13). Örn and
Klasson-Wehler (23) demonstrated that
2,2´,4,4´-tetraBDE (BDE-47) is biotrans-
formed to HO-PBDEs in rats and mice. 3,5-
Dibromo-2-(2,4-dibromophenoxy)phenol is
a hydroxy-BDE that has been identified in
blood plasma of Baltic salmon (24) at levels
similar to those of the major PBDE con-
geners. Information on the endocrine acti-
vity of hydroxylated PBDEs is presently
limited to the ability of several HO-PBDEs
to bind competitively to the thyroid hor-
mone receptor (25) and to TTR (13). 
Studies showing that many industrial
chemicals are weakly estrogenic compared to
natural estrogens (26–28) have raised con-
cern about their safety. For example, o,p´-
DDT, bisphenol A, nonylphenol, and
various phthalates possess estrogenic activity
(27). The presumption is that these xenoe-
strogens may disrupt normal endocrine func-
tion, which can lead to reproductive failure
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Articles
Polybrominated diphenyl ethers (PBDEs) are used in large quantities as additive flame retardants
in plastics and textile materials. PBDEs are persistent compounds and have been detected in
wildlife and in human adipose tissue and plasma samples. In this study, we investigated the
(anti)estrogenic potencies of several PBDE congeners, three hydroxylated PBDEs (HO-PBDEs),
and differently brominated bisphenol A compounds in three different cell line assays based on
estrogen receptor (ER)-dependent luciferase reporter gene expression. In human T47D breast
cancer cells stably transfected with an estrogen-responsive luciferase reporter gene construct
(pEREtata-Luc), 11 PBDEs showed estrogenic potencies, with concentrations leading to 50%
induction (EC50) varying from 2.5 to 7.3 µM. The luciferase induction of the most potent HO-
PBDE [2-bromo-4-(2,4,6-tribromophenoxy)phenol] exceeded that of estradiol (E2), though at
concentrations 50,000 times higher. As expected, brominated bisphenol A compounds with the
lowest degree of bromination showed highest estrogenic potencies (EC50 values of 0.5 µM for 3-
monobromobisphenol A). In an ERα-specific, stably transfected human embryonic kidney cell
line (293-ERα-Luc), the HO-PBDE 4-(2,4,6-tribromophenoxy)phenol was a highly potent estro-
gen with an EC50 < 0.1 µM and a maximum 35- to 40-fold induction, which was similar to E2. In
an analogous ERβ-specific 293-ERβs-Luc cell line, the agonistic potency of the 4-(2,4,6-tribro-
mophenoxy)phenol was much lower (maximum 50% induction compared to E2), but EC50 values
were comparable. These results indicate that several pure PBDE congeners, but especially HO-
PBDEs and brominated bisphenol A-analogs, are agonists of both ERα and ERβ receptors, thus
stimulating ER-mediated luciferase induction in vitro. These data also suggest that in vivo metab-
olism of PBDEs may produce more potent pseudoestrogens. Key words: ER-CALUX, estrogenic-
ity, flame retardants, hydroxylated compounds, polybrominated diphenyl ethers. Environ Health
Perspect 109:399–407 (2001). [Online 27 March 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p399-407meerts/abstract.html
and cancer of estrogen-sensitive tissues in
humans and wildlife (29). Antiestrogenic
activity by anthropogenic compounds has
received less attention (30). Although the
inhibition of hormone action and the result-
ing toxicological consequences have not been
demonstrated conclusively, antiestrogenic
action could critically affect sensitive repro-
ductive and developmental processes as well
(30). To date there have been no reports
investigating the (anti)estrogenic activities of
PBDEs and HO-PBDEs. 
The aim of this study was to determine
the (anti)estrogenicity of 17 PBDE con-
geners. We also examined three hydroxylated
PBDEs that have halogen substitution pat-
terns similar to those of thyroid hormones.
The (anti)estrogenic activity of these com-
pounds was tested in vitro, using an estro-
gen-responsive luciferase reporter cell line
(T47D.Luc) (31). We compared the struc-
ture–activity relationships for (anti)estro-
genicity of PBDE and HO-PBDE congeners
with numerous other brominated flame
retardants, such as differently brominated
bisphenol A compounds. We also tested the
most potent PBDEs and HO-PBDEs
observed in T47D.Luc cells for estrogen
receptor specificity using 293 human embry-
onic kidney cells stably transfected with
recombinant human estrogen receptor (ERα
or ERβs) cDNA and the luciferase reporter
gene construct (32–34). 
Materials and Methods
Chemicals. The 17 PBDE congeners (> 98%
pure; Figure 1, Table 1) were synthesized as
described earlier (35,36). Three HO-PBDEs,
4-(2,4,6-tribromophenoxy)phenol (T2-like
HO-BDE), 2-bromo-4-(2,4,6-tribromophe-
noxy)phenol (T3-like HO-BDE), and 2,6-
dibromo-4-(2,4,6-tribromophenoxy)phenol
(T4-like HO-BDE) (Figure 1) were synthe-
sized as described by Marsh et al. (25) and
were at least 99% pure. We use the abbrevia-
tions for these HO-PBDEs (T2-like, T3-like-,
T4-like HO-BDE) according to their resem-
blance in halogen substitution patterns to the
thyroid hormones 3,5-diiodothyronine (3,5-
T2), 3,3´,5-triiodothyronine (T3), and
3,3´,5,5´-tetraiodothyronine (T4). The core
structure of PBDEs and the structures of the
HO-PBDEs used in this study are shown in
Figure 1, including the structure of the analog
4-phenoxyphenol. The numbering system for
individual PBDE congeners is based on the
numbering system applied to PCBs (37).
4-Phenoxy-phenol and bisphenol A were
obtained from Aldrich Chemical Company
(Bornem, Belgium). 17β-Estradiol (E2; 99%)
and ethanol (100%, pro analysis) were pur-
chased from Sigma Chemical Company (St.
Louis, MO, USA). ICI 182,780 was a gift
from A. Wakeling, Zeneca Pharmaceuticals
(Macclesfield, Cheshire, UK). 3-
Monobromobisphenol A (MBBPA; 96.5%
pure, with 3.5% 3,3´-dibromobisphenol A),
3,3´-dibromobisphenol A (diBBPA; 99.4%
pure, with 0.6% 3,3´,5-tribromobisphenol
A), and 3,3´,5-tribromobisphenol A
(triBBPA; 100% pure) were synthesized by
bromination of bisphenol A using bromine in
acetic acid at room temperature. The test
chemicals and E2 were dissolved in ethanol or
dimethyl sulfoxide (DMSO; 99.9% pure,
Janssen Chimica, Geel, Belgium) for use in
the in vitro assays.
Cell culture. We used the human T47D
breast cancer cell line stably transfected with
an estrogen-responsive luciferase reporter gene
construct (pEREtata-Luc) (31) to study the in
vitro (anti)estrogenic activity of PBDEs and
HO-PBDEs. The T47D.Luc cells were cul-
tured in a 1:1 mixture of Dulbecco’s Modified
Eagle’s (DMEM) medium and Ham’s F12
(DF) medium (Gibco Brl, Life Technologies,
Breda, The Netherlands) supplemented with
sodium bicarbonate, nonessential amino acids,
sodium pyruvate, and 7.5% fetal calf serum
(heat inactivated) at 37°C and 7.5% CO2.
The preparation of the stably transfected
293-Luc cell lines (ERα and ERβs) has been
described in detail elsewhere (32). Briefly,
human 293 embryonal kidney (HEK) cells
(ATCC, American Type Culture Collection,
Rockville, MD, USA) were stably trans-
fected with the pEREtata-Luc construct
(31,32) cotransfected with an antibiotic
resistance gene. This cell line was subse-
quently transfected with a recombinant
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Figure 1. Structure of PBDEs, the three hydroxylated PBDEs, 4-phenoxyphenol, and the differently brominated bisphenol A analogs. The hydrogens have been
omitted for clarity.
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human estrogen receptor (ERα or a short
form of ERβ, ERβs) cDNA and a different
antibiotic resistance gene. The 293-ERα-
and 293-ERβs-Luc cell lines were cultured
in a 1:1 mixture of DMEM and DF
medium supplemented with 7.5% fetal calf
serum (heat inactivated) at 37°C and 7.5%
CO2. 
ER-CALUX assay. We performed the
T47D.Luc-based assay as described previ-
ously (31). The cells were trypsinized, resus-
pended in assay medium, and seeded in
96-well plates (Packard, Meriden, CT, USA)
at a density of 5,000 cells per well in 100 µL.
The assay medium consisted of phenol red-
free DF and fetal calf serum treated with 5%
dextran-coated charcoal (DCC-FCS). DCC-
FCS was prepared as described by Horwitz
and McGuire (38). After 24 hr, when wells
were approximately 50% confluent, the
assay medium was renewed. After another
24 hr, the assay medium was replaced by
incubation medium (for preparation, see
below), containing DMSO or ethanol stock
solutions of the test compounds or estradiol.
Solvent concentrations did not exceed 0.1%.
The incubation medium was removed after
an incubation of 24 hr at 37°C in an atmos-
phere of 7.5% CO2. Cells were washed twice
with 100 µL phosphate-buffered saline
(PBS) and subsequently lysed in 30 µL low
salt (LS) buffer containing 10 mM Tris (pH
7.8), 2 mM dithiothreitrol (DTT), and 2
mM 1,2-diaminocyclohexane-N,N,N´,N´-
tetraacetic acid. After 10 min of incubation
on ice, the 96-well plates were frozen at
–80°C for a minimum of 30 min and maxi-
mum of 1 day to lyse the cells. The plates
were thawed on ice and shaken for 5 min at
room temperature. We measured luciferase
activity in a luminometer (Labsystems
Luminoscan RS, Breda, The Netherlands)
with automatic injection of 100 µL flash mix
(pH 7.8) per well containing 470 µM
luciferin, 20 mM trycine, 1.07 mM
(MgCO3)4Mg(OH)2.5H2O, 2.67 mM
MgSO4, 0.1 mM EDTA, 5 mM ATP, and 2
mM DTT (pH 7.8). 
293-ERα- and 293-ERβs-Luc assay. The
293-ERα- and 293-ERβs-Luc-based assays
were performed similarly to the ER-CALUX
assay and have been described previously
(32–34). Briefly, cells were trypsinized and
resuspended in assay medium composed of
phenol red-free DF containing 30 nM selen-
ite, 10 µg/mL transferin, and 0.2% BSA
supplemented with 5% DCC-FCS. The
cells were seeded in 96-well plates at a den-
sity of 15,000 cells per well in 200 µL assay
medium. After 48 hr the cells were 50–60%
confluent, and the assay medium was
replaced by incubation medium (i.e., con-
taining a 1,000-fold dilution of test com-
pounds) as described for the ER-CALUX
assay. After an incubation of 24 hr at 37°C
in an atmosphere of 7.5% CO2, the plates
were transferred to ice and the medium was
removed by suction. Luciferase production
was assayed as described above for the ER-
CALUX assay.
Exposure of cells. Before the T47D.Luc
cell incubations, the PBDE and HO-PBDE
stock solutions (prepared in DMSO) and
the brominated bisphenol compounds (pre-
pared in ethanol) were diluted 1,000-fold in
assay medium in a 48-well plate (to obtain a
solvent-concentration of 0.1% v/v) and
thoroughly shaken, and 100 µL was added
to the cells in 96-well plates. The nominal
concentrations of the toxicants in the
medium were 0.05, 0.1, 0.5, 1.0, and 5 µM,
and for potent compounds concentrations
of 2.5 and 10 µM were also included. For
each experiment, we included a complete E2
standard curve (1–100 pM, 7 different con-
centrations in total). In addition, we tested
three calibration points (0, 10, and 30 pM
E2) on every 96-well plate within an experi-
ment.
For the 293-ERα- and 293-ERβs-Luc
assays, the DMSO stock solutions of the
tested compounds were diluted 1,000-fold
in the appropriate assay medium. The nomi-
nal concentrations of the toxicants exposed
to the cells were 1.0, 5.0, and 10 µM. For
each experiment a complete E2 standard
curve (0.001–10,000 pM in eight different
concentrations) was included. For all three
ER-CALUX assays, we tested every toxicant
concentration in triplicate and repeated each
assay at least twice.
Antiestrogenic effects. We tested the pos-
sible antiestrogenic effects of the com-
pounds in the ER-CALUX assay at the same
nominal concentrations as for the estrogenic
activity screening. The T47D.Luc cells were
coincubated with an E2 concentration of 10
pM. This E2 concentration was the approx-
imate EC50 for the induction of luciferase
activity (31). The percentage (v/v) of
DMSO present during these antiestrogenic-
ity incubations was 0.2%. An antiestro-
genic effect in this assay was defined by the
capacity of a chemical to inhibit the
luciferase activity induced by the approxi-
mate EC50 concentration of E2. The per-
centage inhibition is calculated according to
the equation
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Table 1. Estrogenic activity of polybrominated diphenyl ethers (PBDEs), hydroxylated PBDEs (HO-PBDEs),
and brominated bisphenols in the ER-CALUX assay with T47D.Luc cells.
Relative Relative Maximum
Bromine LOEC potency potency luciferase
Compound substitution (µM)a (LOEC)b EC50 (µM)c (EC50)d induction (%)e
Estradiol 1.0 × 10–6 — 1.0 × 10–5 — 100
PBDEs
BDE-15 4,4´ NA — — — < 1
BDE-28 2,4,4´ 0.5 2.0 × 10–6 NA — 43 ± 2
BDE-30 2,4,6 0.5 2.0 × 10–6 3.4 2.9 × 10–6 114 ± 31
BDE-32 2,4´,6 0.05 2.0 × 10–5 5.1 1.9 × 10–6 85 ± 13
BDE-47 2,2´,4,4´ 5.0 2.0 × 10–7 NA — 6 ± 1
BDE-51 2,2´,4,6´ 0.5 2.0 × 10–6 3.1 3.2 × 10–6 85 ± 18
BDE-71 2,3´,4´,6 0.5 2.0 × 10–6 7.3 1.4 × 10–6 62 ± 8
BDE-75 2,4,4´,6 0.5 2.0 × 10–6 2.9 3.5 × 10–6 53 ± 10
BDE-77 3,3´,4,4´ NA — — — < 1
BDE-85 2,2´,3,4,4´ 5.0 2.0 × 10–7 NA — 8 ± 1
BDE-99 2,2´,4,4´,5 5.0 2.0 × 10–7 NA — 2 ± 1
BDE-100 2,2´,4,4´,6 0.05 2.0 × 10–5 2.5 4.1 × 10–6 57 ± 10
BDE-119 2,3´,4,4´,6 0.05 2.0 × 10–5 3.9 2.6 × 10–6 25 ± 4
BDE-138 2,2´,3,4,4´,5´ NA — — — 1 ± 1
BDE-153 2,2´,4,4´,5,5´ NA — — — < 1
BDE-166 2,3,4,4´,5,6 NA — — — < 1
BDE-190 2,3,3´,4,4´,5,6 NA — — — < 1
HO-PBDEs
4-Phenoxyphenol 0.5 2.0 × 10–6 1.7 5.8 × 10–6 195 ± 17
T2-like HO-BDE 0.05 2.0 × 10–5 0.1 1.0 × 10–4 160 ± 11
T3-like HO-BDE 0.5 2.0 × 10–6 0.5 2.0 × 10–5 119 ± 22
T4-like HO-BDE NA — — — < 1
(Brominated) bisphenols
Bisphenol A 0.01 1.0 × 10–4 0.3 3.3 × 10–5 200 ± 15
MBBPA 0.1 1.0 × 10–5 0.5 2.0 × 10–5 125 ± 3.1
DiBBPA 0.1 1.0 × 10–5 0.4 2.5 × 10–5 136 ± 1
TriBBPA 0.5 2.0 × 10–6 > 10 < 1.0 × 10–6 80 ± 3
TBBPA NA — — — < 1
NA, Not achieved.
aLowest observed effect concentration; lowest concentration where luciferase activity is detected. bRatio between dose
of compound and estradiol needed to achieve an estrogenic effect [LOEC(E2) / LOEC (compound)]. cConcentration at which
the induction of luciferase activity is 50% of the maximum. dRatio between EC50 of the compound and EC50 of estradiol.
ePercent luciferase activity induced by the test compound relative to the maximum luciferase activity of E2 (30 pM).
Maximum concentration of the test compounds was 10 µM, except for BDE-47 and BDE-85 (maximum: 5 µM).
[1]
where I is the percent inhibition, and Ltest,
Lcontrol, and LE2 are the average luciferase
activity of three test wells, three control wells
and six wells incubated with 30 pM of E2,
respectively. Using Equation 1, a compound
without antagonistic activity will show the
same luciferase induction as 10 pM of E2, [i.e.,
63.3 ± 7.5% (see “Results”)]. On each plate a
positive control of 10 nM of the competitive
ER antagonist ICI 182,780 was included in
triplicate. ICI 182,780 produces virtually total
antagonism of E2-induced luciferase activity at
this concentration [i.e., activity measured is
equal to solvent control levels (31)].
Cytotoxicity. We measured possible cyto-
toxic effects of the tested compounds in the
bioassays using 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide activity
(39). To determine cytotoxic effects, we
seeded cells and exposed them to the test
compounds in the same manner as outlined
in their corresponding assay procedures.
Dose–response curves and statistics.
Possible dose–response relations were
described by the sigmoidal function 
y = a0 + a1/{1 + exp[(a2 – x)/a3]} [2]
using SlideWrite Plus 4.0 (Advanced
Graphics Software, Carlsbad, CA, USA),
where y is the induction of luciferase activity
compared to controls for estrogenic effects,
or inhibition [I (%), Equation 1] for antie-
strogenic effects, x is the logarithm of the
dose, and a 1 is the maximum y-value. We
tested the significance of the data fits using
one-way analysis of variance at p < 0.05. 
Results
Cytotoxicity
In the concentration range of 0.01–10 µM,
none of the incubations of the PBDEs or
HO-PBDEs showed any significant effect on
MTT activity relative to the solvent control
(data not shown). Furthermore, no cytotoxic
effect could be observed by microscopic
examination in this concentration range.
I % 100 1
L – L
L – L
test control
E2 control
( ) = −


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Figure 2. Estrogenic activity of PBDEs in the T47D.Luc cells. Luciferase induction (%) relative to the maximum induction by E2 (30 pM) after 24-hr exposure to sev-
eral concentrations of (A) BDE-28, -51, -75, -85 and -119, and (B) BDE-30, -32, -47, -71, and -100. Points are means (n = 3) ± SD (bars) for each concentration.
Figure 3. The estrogenic activity of hydroxy-PBDEs in the T47D.Luc cells.
Luciferase induction (%) relative to the maximum induction by E2 (30 pM) after
24-hr exposure to several concentrations of T2-like HO-BDE [4-(2,4,6-tribro-
mophenoxy)phenol], T3-like HO-BDE [2-bromo-4-(2,4,6-tribromophenoxy)phe-
nol], T4-like HO-BDE [2-6-dibromo-4-(2,4,6-tribromophenoxy)phenol], and
4-phenoxyphenol. Points are means (n = 3) ± SD(bars) for each concentration.
Figure 4. The estrogenic activity of differently brominated bisphenols in the
T47D.Luc cells. Luciferase induction (%) relative to the maximum induction by
E2 (30 pM) after 24-hr exposure to several concentrations of bisphenol A
(BPA), monobromobisphenol A (mono), dibromobisphenol A (di), tribromo-
bisphenol A (tri), and tetrabromobisphenol A (tetra). Points are means (n = 3) ±
SD (bars) for each concentration.
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PBDE concentrations could not exceed 10
µM because of solubility problems and slight
cytotoxic effects (data not shown).
ER-CALUX Assay Based on
T47D.Luc Cells
Estrogenic effects. Seventeen PBDE con-
geners and 3 HO-PBDEs were tested in the
T47D.Luc-based ER-CALUX assay for their
estrogenic and/or antiestrogenic properties.
Eleven PBDEs exhibited luciferase induction
(Table 1) in a dose-dependent manner
(Figure 2). The most potent PBDE-congeners
[2,2´,4,4´,6-pentaBDE (BDE-100) >
2,4,4´,6-tetraBDE (BDE-75) > 2,2´,4,6´-
tetraBDE (BDE-51) > 2,4,6-triBDE (BDE-
30) > 2,3´,4,4´,6-pentaBDE (BDE-119)]
showed EC50 values within a small concentra-
tion range of 2.5 to 3.9 µM (Table 1). These
PBDE agonists were 250,000–390,000 times
less potent than the natural ligand, E2.
The T4-like HO-BDE compound
demonstrated no estrogenic effect up to 10
µM (Figure 3). In contrast, the T3-like HO-
BDE and T2-like HO-BDE showed the
highest estrogenic potencies (EC50 0.5 and
0.1 µM, respectively) among all compounds
tested in this study (Table 1, Figure 3). The
compound 4-phenoxy-phenol was included
for comparison because it is structurally
analogous to the hydroxylated PBDEs. The
T2-like and T3-like HO-BDEs induced
maximum luciferase activity at 0.5 µM and
1.0 µM respectively, and this maximum
luciferase activity (160 ± 11 and 119 ± 22
%) exceeded that of the natural hormone E2
(Table 1).
Of the brominated bisphenols tested,
MBBPA and diBBPA showed estrogenic
activities comparable to the T3-and T2-like
HO-BDE, with EC50 values of 0.5 and 0.3
µM, respectively (Figure 4, Table 1). The
maximum luciferase activity of bisphenol A,
MBBPA, and diBBPA exceeded the maxi-
mum activity induced by E2 (Figure 4).
Bisphenol A and 4-phenoxyphenol had the
highest maximum luciferase activity of 199 ±
15% and 195 ± 17%, respectively, relative to
the maximum of E2 (set at 100%, Figure 4).
Tetrabromobisphenol A (TBBPA) showed
no estrogenic potency within the tested con-
centrations.
Antiestrogenic effects. The antiestrogenic
potency of PBDEs was determined in the
ER-CALUX bioassay by treating T47D.Luc
cells with 0.01 to 10 µM concentrations of
PBDEs in the presence of 10 pM of E2.
Alone, this E2 concentration produced a
luciferase induction of 63.3 ± 7.5% of the
maximum (Table 2). At the 10 nM concen-
tration, the ER antagonist ICI 182,780
completely inhibited the luciferase activity
induced by 10 pM E2. Only 2,2´,4,4´,5,5´-
hexaBDE (BDE-153), 2,3,4,4´,5,6-hexaBDE
(BDE-166), and 2,3,3´,4,4´,5,6-hepta-BDE
(BDE-190), which did not induce luciferase
activity alone (up to 10 µM, Table 1),
reduced E2-induced luciferase activity (Table
2). Moreover, these three PBDE congeners
inhibited the E2-induced activity in a dose-
dependent manner (Figure 5).
293-ERα- and 293-ERβs-293-Luc
Cell Lines
As in previous findings (32–34), the
luciferase activity for the 293-ERα-Luc assay
was more sensitive and responsive to E2 than
the 293-ERβs-Luc assay (data not shown). In
the present study, the 293-ERα-Luc assay
had a 35-fold maximum induction relative to
control, which was reached at about 100 pM
E2. The lowest observed effect concentration
(LOEC) and EC50 for E2 in the 293-ERα-
Luc assay were 2.6 pM and 11.9 pM, respec-
tively. In the 293-ERβs-Luc assay, a 16-fold
maximum induction was attained at about
1,000 pM E2. The LOEC was 15.3 pM and
the EC50 was 90.2 pM for E2.
The most potent xenoestrogens in the
ER-CALUX—BDE-30, BDE-100, 4-phe-
noxy-phenol, and T2-like HO-BDE—were
investigated for estrogenicity in the 293-
ERα- and ERβs-Luc-based assays. Relative
to the E2 maximum luciferase induction, the
induction of the highest concentration of
BDE-30 (10 µM) in the 293-ERα-Luc and
293-ERβs-Luc cell lines (34.2 ± 2.2% and
7.8 ± 3.1%, respectively; Figure 6A,B) was
much lower compared to the T47D.Luc cell
line (114 ± 31%). At the same concentration,
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Table 2. Antiestrogenic activity of PBDEs and HO-PBDEs in combination with 10 pM E2 in the ER-CALUX
assay with T47D.Luc cells.
Percent
luciferase induction 
relative to 
Bromine Concentration IC50 maximum
Compound substitution (µM) (µM)a E2 (30 pM)b
Estradiol 1.0 × 10-5 — 63.3 ± 7.5
ICI 182,780 0.01 1.0 × 10-5 0 ± 1.2
PBDEs
BDE-15 4,4´ 5 — 62.1 ± 1.5
BDE-28 2,4,4´ 0.5 — 80.1 ± 12.9
5.0 — 111.5 ± 3.3
BDE-30 2,4,6 0.5 — 31 ± 16
5.0 — 47 ± 10
BDE-32 2,4´,6 0.5 — 64.8 ± 6.4
5.0 — 106.8 ± 4.0
BDE-47 2,2´,4,4´ 0.5 — 45.9 ± 5.9
5.0 — 75.0 ± 4.8
BDE-51 2,2´,4,6´ 0.5 — 108.0 ± 8.2
5.0 — 95.0 ± 4.8
BDE-71 2,3´,4´,6 0.5 — 52 ± 6
5.0 — 62 ± 1
BDE-75 2,4,4´,6 0.5 — 41.9 ± 7.6
5.0 — 55.1 ± 12.6
BDE-77 3,3´,4,4´ 5.0 — 64.9 ± 2.2
BDE-85 2,2´,3,4,4´ 5.0 — 68.9 ± 2.9
BDE-99 2,2´,4,4´,5 5.0 — 62.8 ± 2.2
BDE-100 2,2´,4,4´,6 0.5 — 86.6 ± 3.7
5.0 — 108.0 ± 15.4
BDE-119 2,3´,4,4´,6 0.5 — 102.6 ± 5.4
5.0 — 92.5 ± 12.7
BDE-138 2,2´,3,4,4´,5´ 5.0 — 56.9 ± 6.6
BDE-153 2,2´,4,4´,5,5´ 0.5 3.1 67.9 ± 3.4
5.0 47.4 ± 9.2
BDE-166 2,3,4,4´,5,6 0.5 0.8 52.4 ± 4.1
5.0 25.3 ± 4.9
BDE-190 2,3,3´,4,4´,5,6 0.5 1.0 74.1 ± 5.8
5.0 43.8 ± 3.7
HO-PBDEs
4-Phenoxyphenol 0.5 — 67.0 ± 9.6
5.0 — 209.3 ± 25.7
T2-like HO-BDE 0.5 — 169.4 ± 14.8
5.0 — 178.5 ± 13.1
T3-like HO-BDE 0.5 — 82.6 ± 7.6
5.0 — 96.1 ± 12.2
T4-like HO-BDE 0.5 — 62.1 ± 5.2
5.0 — 65.1 ± 13.8
aConcentration at which the induction of luciferase activity by E2 (EC50 concentration of 10 pM) is inhibited by 50%. bThe
luciferase activity induced by the test compound and E2 (EC50 concentration of 10 pM) as a percentage of the maximum
activity (E2, 30 pM). 
BDE-100 showed an induction < 2% in the
293-ERβs-Luc assay, whereas the 293-ERα-
Luc assay was more responsive (about 20%
relative induction). However, EC50 values of
BDE-30 and BDE-100 in the 293-ERα-
Luc-assay (< 5.0 µM) and the ER-CALUX
assay (3.4 and 2.5 µM, respectively) are
comparable. 
The T2-like HO-BDE induced maxi-
mum response in the 293-ERα-Luc cells to
the same maximum level as E2 (Figure 6A),
even at the lowest concentration tested (0.1
µM). With the 293-ERβs-Luc assay, the T2-
like HO-BDE showed 50% of the maxi-
mum E2 induction at 5.0 µM (Figure 6B).
The structural analog 4-phenoxyphenol
induced luciferase in the 293-ERβs-Luc to
126 ± 12 and 144 ± 11% at concentrations
of 5.0 µM and 10 µM, respectively (Figure
6B). The luciferase induction by 4-phe-
noxyphenol in the 293-ERα-Luc assay simi-
larly exceeded the maximal E2 induction
(Figure 6A), but only at the 10 µM concen-
tration level. The EC50 value of this com-
pound in the 293-ERα- and 293-ERβs-Luc
assays is in the same range (< 5.0 µM).
Discussion
In this study we investigated both the estro-
genic and antiestrogenic activity of several
PBDE congeners, three hydroxylated
PBDEs, and some brominated bisphenol A
compounds in vitro. To our knowledge, no
studies have been performed on the agonistic
or antagonistic activity of these compounds
in vivo or in vitro at the level of the estrogen
receptor. Of the 17 selected PBDEs, 11 con-
geners were able to exert estrogenic activities
in T47D.Luc cells at LOECs as low as 0.05
µM, and EC50 values ranging from 2.5 to
7.3 µM. In the same ER-CALUX assay, the
organochlorine pesticides methoxychlor,
endosulfan, and chlordane had a similar
potency for luciferase induction, about 1.0 ×
10–6 times the potency of E2 (31). 
PBDE congeners with the highest estro-
genic activity in the T47D.Luc cells were
2,2´,4,4´,6-pentaBDE (BDE-100), 2,4,4´,6-
tetraBDE (BDE-75), and 2,2´,4,6´-
tetraBDE (BDE-51). BDE-100 in particular
has often been reported among the more
common PBDEs found in humans and
other mammals (2,7,9). The common struc-
tural features among the estrogenic PBDEs
are two ortho (2,6)-bromine atoms on one
phenyl ring, at least one para-bromine atom
(preferably on the same phenyl-ring as the
ortho bromines), and nonbrominated ortho-
meta or meta carbons on the other phenyl
ring. This structure–activity relationship
resembles the one suggested by Korach et al.
(40) for hydroxylated PCBs in a competitive
binding assay, where congeners with the
highest binding affinity for the estrogen
receptor contained an unsubstituted phenol
ring with a p-hydroxy group (e.g., 4-
hydroxy-2´,4´,6´-triCB). However, in the
case of the brominated diphenyl ethers, the
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Figure 5. The antiestrogenic activity of PBDEs in the T47D.Luc cells. The luciferase induction (%) relative
to the maximum induction by E2 (30 pM) after 24-hr exposure to several concentrations of BDE-153
(2,2´,4,4´,5,5´-hexaBDE), BDE-166 (2,3,4,4´,5,6-hexaBDE), and BDE-190 (2,3,3´,4,4´,5,6-heptaBDE), in the
presence of 10 pM E2 (with luciferase induction of 63.3 ± 7.5% of the maximum induction). Points are
means (n = 3) ± SD (bars) for each concentration. 
Figure 6. The estrogenicity of PBDEs and HO-PBDEs in the (A) 293-ERα-Luc and (B) 293-ERβs-Luc cells. The luciferase induction (%) relative to the maximum
induction by E2 (1,000 pM) after 24-hr exposure to three concentrations of BDE-30 (2,4,6-triBDE), BDE-100 (2,2´,4,4´,6-pentaBDE), T2-like HO-BDE [4-(2,4,6-tribro-
mophenoxy)phenol], and HO-DE (4-phenoxyphenol). Points are means (n = 3) ± SD (bars) for each concentration. 
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para position is occupied by a bromine
atom. In addition, Connor et al. (41)
observed that hydroxy-PCB congeners hav-
ing one or no chlorine atoms ortho to the
para-hydroxyl group and 2,4,6-trichlorina-
tion on the nonphenolic ring induced
luciferase activity from 20 to 60% (at 5 µM)
of the E2 maximum induction in HeLa.Luc
cells. Introduction of a single 2- or 3-chloro
substituent into the phenolic ring signifi-
cantly decreased the ER binding affinity
(41). In case of PBDEs, the introduction of
a single 3-bromine substituent next to the
para-bromine atom on one ring significantly
reduced the estrogenic potency [e.g., EC50-
value of 2,4,4´,6-tetraBDE (2.9 µM) is
lower compared to 2,3´,4,4´,6-pentaBDE
(3.9 µM)], whereas the introduction of a sin-
gle 2-bromine (ortho) substituent next to the
para-bromine increased the estrogenic
potency, though not significantly (EC50
value of 2,2´,4,4´,6-pentaBDE: 2.5 µM).
Though not very likely, hydroxylated
PBDE metabolites formed in situ may have
been involved in the estrogenic effects of the
PBDEs in the T47D.Luc cells. T47D.Luc
cells possess some metabolic capabilities such
as cytochrome P450-mediated hydroxylation
of estrogens and xenobiotics. P450 1A
(42,43), P450 1B (43), and 17β-hydroxys-
teroid dehydrogenase (44) have been
reported in T47D.Luc cells. However, few
data are available on the metabolism of
PBDEs, and in the only two studies known
reporting PBDE metabolism, the major
compound excreted was the parent PBDE.
Örn and Klasson-Wehler (23) detected five
hydroxylated PBDE metabolites (by GC/MS
analyses) in feces and various tissues of rats
and mice dosed orally with 2,2´,4,4´-
tetraBDE (BDE-47), but the major com-
pound excreted was BDE-47. Larsen et al.
(45) reported a low (about 1% of the total
given dose) biliary and urinary excretion of
possible metabolites of 2,2´,4,4´,5-pentaBDE
(BDE-99) in conventional and bile-duct can-
nulated rats. 
The hydroxylated PBDE congeners tested
in our study have structural resemblance with
the thyroid hormones 3,5-diiodothyronine
(T2), 3,3´,5-triiodothyronine (T3), and
3,3´,5,5´-tetraiodothyronine (thyroxine, T4).
These HO-PBDEs have been reported to
bind to the human α- and β-thyroid hor-
mone receptor (THR) (25) and compete with
the natural hormone T4 for binding to a
human thyroid hormone transport protein,
transthyretin (13) in vitro. Several interactions
between the thyroid hormone receptor- and
estrogen receptor-mediated pathways have
been reported, affecting testis development
(46) and behavior (47). Since the structure of
the hydroxy-phenyl ring in compounds inter-
acting with the ER and THR (hydroxylated
PCBs, hydroxylated PBDEs) is similar (with
differences in halogen substitution), it is
interesting to study the possible interaction
of compounds with both pathways. The
ranking of estrogenic potency in the
T47D.Luc cells of the thyroid hormonelike
HO-PBDEs was T2-like HO-BDE (EC50,
0.1 µM) > T3-like HO-BDE (EC50, 0.5
µM) >>> T4-like HO-BDE. The potencies
of the T2-like HO-BDE and T3-like HO-
BDE were virtually the same as the potency
of the phenolic industrial chemicals, such as
bisphenol A [0.3 µM (this study), 0.8 µM
(31)] and nonylphenol [0.3 µM (31)] tested
in the same ER-CALUX assay. Bisphenol A
is one of several well-defined phenolic envi-
ronmental estrogens that are known to elicit
estrogen-mediated responses in vivo and in
vitro such as the increased proliferation of
MCF7 human breast cancer cells (48 –51).
The ranking order for estrogenicity of the
hydroxylated PBDEs (Figure 3) was the
reverse order found for binding to the
human α- and β-thyroid hormone receptor
(THR) (25) and human transthyretin
(TTR) (13) in vitro. This comparison
between ER and THR interactions empha-
sizes that nonbromination of the phenolic
ring is necessary for optimum interaction
with the ER, which was also found for HO-
PCBs (40,41). Conversely, like the interac-
tion of the natural, iodine-containing T2,
T3, and T4 thyroid hormones with THR
and TTR, increasing bromination in adja-
cent positions on the HO-PBDEs increases
THR and TTR binding affinity. The same is
true for the brominated bisphenols. The
ranking of estrogenic potency in the
T47D.Luc cells of the brominated bisphe-
nols was monoBBPA (EC50, 0.5 µM) ~
diBBPA (EC50, 0.3 µM) >> triBBPA (EC50
> 10 µM) >>> TBBPA, and was also the
reverse order found for interaction with
human TTR in vitro (13). The addition of
bromine atoms in the meta position of the
aromatic ring (in diBBPA) had no signifi-
cant effect on the estrogenic potency. This is
in line with results published by Perez et al.
(51), where the estrogenicity of 2,2-bis(4-
hydroxy-3-methylphenyl)propane (i.e., one
methylgroup in the meta position of one aro-
matic ring) in a bioassay with MCF7 human
breast cancer cells was not changed com-
pared to bisphenol A. However, the intro-
duction of two bromine atoms in the meta
position of one aromatic ring drastically
decreased the estrogenic potency (triBBPA,
this study). 
In contrast to the HO-PBDEs, the
major HO-PCBs identified in human serum
were mostly antiestrogenic but exhibited low
to nondetectable estrogenic activities in sev-
eral in vitro bioassays (48). At concentrations
as high as 10 M, several 4-OH-substituted
PCBs were not estrogenic toward binding of
rat uterine ER. Furthermore, the same HO-
PCBs did not induce the proliferation of
MCF7 human breast cancer cells, or the
luciferase activity of transiently transfected
HeLa.Luc cells and MCF7 cells. Unlike the
present HO-PBDEs, these HO-PCBs pos-
sessed tri- to tetrachlorine substitution on
the phenolic ring. In this study, only three of
the PBDEs [2,2´,4,4´,5,5´-hexaBDE (BDE-
153), 2,3,4,4´,5,6-hexaBDE (BDE-166),
and 2,3,3´,4,4´,5,6-hepta-BDE (BDE-190)]
showed antiestrogenic activities with concen-
trations resulting in 50% inhibition (IC50
values) ranging from 0.8 to 3.1 µM. These
PBDEs are likely not metabolized in situ
because the congeners are hexa- or hept-
abromine substituted, have two para-
bromines, and have no adjacent or ortho-meta
brominated carbons. Since the T47D.Luc
cells express a functional Ah receptor, it may
be possible that the anti-estrogenicity of
these PBDEs is Ah receptor-mediated, as is
the case for 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) and several other antiestro-
gens (52). BDE-153, -166, and -190
induced the highest maximal luciferase activ-
ity in an Ah receptor CALUX assay based on
H4IIE.Luc cells, among the same set of 17
PBDEs (21). 
The antiestrogenicity of Ah receptor lig-
ands is directly correlated to their affinity for
the Ah receptor and their CYP1A-inducing
potency (52). As shown for TCDD-treated
MCF7 cells (53), the result is enhanced
estrogen catabolism, and lower availability of
estrogen to the cell. This correlation between
structure-antiestrogenicity– and structure-
CYP1A–inducing potency has been shown
for various halogenated aromatics such as
TCDD and non-ortho PCBs in vivo and in
vitro (55,56). The exact mechanism of antie-
strogenicity is probably specific to species,
cell type, and the estrogen-responsive gene.
Other possible cellular mechanisms of Ah
receptor-mediated antiestrogenicity of BDE-
153, -166, and -190 may be that the Ah
receptor decreases the binding of the ER to
the estrogen-responsive element, or the Ah
receptor could act as a repressor by inhibiting
the binding of other transcription factors
(ER) or the disruption of promotor function.
Interestingly, the HO-PBDEs induced
luciferase to a higher maximum activity than
the maximum induction generated by E2,
though at higher concentrations. This has
been shown for several other compounds
mimicking the natural estrogen in reporter
gene assays. Legler et al. (31) reported this
phenomenon for the environmental estro-
gens genistein, nonylphenol, bisphenol A,
o,p´-DDT, and methoxychlor in the same
T47D.luc cells. Routledge and Sumpter (57)
showed that genistein and 4-tert-octylphenol
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induced luciferase activity at a higher level
than estradiol in a recombinant yeast strain.
The mechanism of this high induction is not
yet resolved, but effects on luciferase stability
or stimulation of the expression of the recep-
tor or co-activation factors are hypothesized
to be involved (31). 
We detected no striking differences in the
relative binding affinities for the tested com-
pounds between ERα or ERβ. However, the
agonistic activity compared to E2 of BDE-30
and BDE-100 was much higher in the 293-
ERα- than in the 293-ERβs-Luc cell line
(Figure 6). Moreover, the agonistic activity of
T2-like HO-BDE, but not 4-phenoxy-phe-
nol, was estrogen-receptor dependent (Figure
6). The induction of luciferase compared to
E2 by T2-like HO-BDE was much higher in
the 293-ERα-Luc assay, whereas the induc-
tion of luciferase by 4-phenoxy-phenol was
not selective to either assay. This would sug-
gest that the presence of a bromine atom
adjacent to the phenolic hydroxyl group is a
disciminating factor leading to a partial ago-
nistic activity in the 293-ERβs-Luc cell line
compared to a full agonistic activity in the
293-ERα-Luc cell line. 
In the same two ER-CALUX assays,
polycyclic musk compounds were selective
to the 293-ERα-Luc but not the 293-ERβs-
Luc assay (32). HO-PCBs with chlorine
atoms only on the nonphenolic ring were
found to bind with purified human ERα
and ERβ with at least a 10-fold greater affin-
ity than HO-PCBs with chlorine atoms on
the phenolic ring (34). However, the bind-
ing preference was 2-fold greater for the ERβ
over the ERα. In the same study, 4-HO-
2´,4´,6´-trichlorobiphenyl and 4-HO-
2´,3´,4´,5´-tetrachlorobiphenyl highly
induced luciferase activity in transiently
transfected 293-ERα-Luc and 293-ERβs-
Luc cells, although the transactivation activ-
ity was higher in the 293-ERα-Luc cells. 
In conclusion, the results from this study
clearly demonstrate that several pure PBDE
congeners, but especially hydroxylated
PBDEs and polybrominated bisphenol A
compounds, induce the estrogen receptor sig-
nal transduction pathway in vitro. The estro-
genic potencies of these flame retardants are
in the same range as the well-known envi-
ronmental estrogen bisphenol A. The struc-
ture–activity relationships of the PBDEs are
in accordance with structure–activity relation-
ships proposed for hydroxylated polychlori-
nated biphenyls. Further, the agonistic
potency in vitro of estrogenic PBDEs and
HO-PBDEs is preferential toward the ERα
relative to ERβ. Because of the high-produc-
tion volume of these compounds and their
accumulation in the environment, further
studies on the possible implications of these
findings for the in vivo situation are necessary. 
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